Skip to content
Clinical Trials – home
SlovakiaBack to Slovakia

Clinical trials in Levoca – page 7

194 clinical trials in Levoca, Slovakia. Every trial is listed in the EU Clinical Trials Register and updated daily.

SlovakiaOur site in SlovakiaKlinickeSkusky.sk(opens in a new tab)
Levoca at a glance
194
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

194 trials in Levoca

Open in trial search

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Study of Verekitug to improve symptoms in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 kappa monoclonal antibody against CRLF2
  • Sponsor:Upstream Bio Inc.

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Laroprovstat
  • Sponsor:AstraZeneca AB

Arteriosclerosis

Not recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Maridebart Cafraglutide
  • Sponsor:Amgen Inc.

Hypertriglyceridaemia

Not recruiting

Long-Term Safety Study of Plozasiran for Adults with High Triglycerides

InvestigationalNo placebo
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Nipocalimab for Adults with Moderate to Severe Sjögren's Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Asthma

Not recruiting

Study on the Effectiveness and Safety of Fluticasone Propionate and Salbutamol Sulfate for Asthma in Patients Aged 12 and Older

Investigational
Countries:SlovakiaSlovakia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Teva Branded Pharmaceutical Products R&D LLC

Study of ISIS 678354 for Patients with Severe High Triglycerides

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:ISIS 678354 sodium salt
  • Sponsor:Ionis Pharmaceuticals Inc.

Obesity

Not recruiting

Study on the Effect of Survodutide on Heart Safety in Patients with Obesity and Cardiovascular or Kidney Disease

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Survodutide
  • Sponsor:Boehringer Ingelheim Espana S.A.

Skin ulcer

Not recruiting

Study on the Effectiveness of Allo-APZ2-CVU for Patients with Long-Term, Non-Healing Venous Leg Ulcers

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:ALLO-APZ2-EB
  • Sponsor:Rheacell GmbH & Co. KG

Psoriatic arthropathy

Not recruiting

Study of sonelokimab injection in adults with active psoriatic arthritis who have not received biological DMARDs treatment before

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:SlovakiaSlovakia
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Other cities in Slovakia

The busiest research cities in the country

All 88 cities in Slovakia

Clinical research in Levoca

What the registry says about research in the country

01 Cardiovascular Research

Innovative research focusing on atherosclerotic cardiovascular disease (ASCVD) treatment optimization. Studies aim to evaluate new therapeutic approaches for patients whose current lipid-modifying treatments aren't providing sufficient results.

  • Cardiovascular event prevention
  • Lipid management therapy
  • Arterial plaque reduction

Research emphasizes improving outcomes for patients with advanced cardiovascular conditions.

02 Stroke Prevention Studies

Comprehensive research into ischemic stroke prevention, particularly focusing on innovative treatments for patients who have experienced acute non-cardioembolic strokes or high-risk transient ischemic attacks.

  • Post-stroke treatment optimization
  • Blood clot prevention
  • Antiplatelet therapy enhancement

Studies evaluate new oral medications against established treatments to improve patient outcomes.

03 Cardiac Rhythm Management

Advanced research targeting atrial fibrillation complications, with a focus on preventing stroke and systemic embolism in at-risk patients.

  • Stroke prevention in AF patients
  • Bleeding risk management
  • Comparative treatment efficacy

Investigations aim to establish superior treatment options with improved safety profiles.

04 Neurological Disorders

Critical research addressing refractory status epilepticus (RSE), evaluating new therapeutic interventions combined with standard care protocols.

  • Emergency seizure management
  • Treatment resistance
  • Novel therapeutic approaches

Studies focus on developing more effective treatments for severe seizure conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.